Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: acamprosate Clear all
Completed Phase 4 Interventional Results available

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Acamprosate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Acamprosate Safe to Use in Individuals With Liver Disease.

NCT04287920
View directory record Official record
Conditions
Alcohol-related Liver Disease
Interventions
Acomprosate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 4, 2026, 8:38 PM EDT
Withdrawn Phase 2 Interventional

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

NCT02064010
View directory record Official record
Conditions
Drug-induced Tardive Dyskinesia
Interventions
SNC-102, Placebo
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 4, 2026, 8:38 PM EDT
Terminated Not applicable Interventional

Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

NCT00425711
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 4, 2026, 8:38 PM EDT
Recruiting Not applicable Interventional

Combining a Smartphone App With Medications to Manage Heavy Drinking

NCT06303778
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Stand Down mobile app, Standard Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 2 Interventional

Acamprosate Treatment: Mechanisms of Action

NCT00004552
View directory record Official record
Conditions
Alcoholism
Interventions
acamprosate (Campral)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 2Phase 3 Interventional

Acamprosate in the Treatment of Binge-Eating Disorder

NCT00511940
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
acamprosate, placebo
Drug · Other
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

NCT03818191
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Center City, Minnesota • Rochester, Minnesota • Newberg, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate in Alcoholics With Comorbid Anxiety or Depression

NCT00330174
View directory record Official record
Conditions
Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
Interventions
Acamprosate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Belmont, Massachusetts • New York, New York • Pickens, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Results available

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

NCT00463346
View directory record Official record
Conditions
Alcohol Dependence, Schizophrenia
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 2 Interventional

Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations

NCT06471686
View directory record Official record
Conditions
Alcohol Use Disorder, Liver Transplant; Complications
Interventions
Acamprosate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Sep 4, 2026, 8:38 PM EDT
Active, not recruiting Phase 1 Interventional

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

NCT07204977
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Acamprosate calcium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 8:38 PM EDT
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 8:38 PM EDT
Withdrawn Phase 4 Interventional

Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)

NCT00655967
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate (Campral), Acamprosate
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 4, 2026, 8:38 PM EDT
Withdrawn Phase 2 Interventional

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

NCT02217007
View directory record Official record
Conditions
Tourette Syndrome
Interventions
SNC-102 sustained release tablet
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence

NCT00385268
View directory record Official record
Conditions
Cocaine Dependence
Interventions
acamprosate, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Early Phase 1 Interventional Results available

Neurophysiological and Acute Pharmacological Studies in FXS Patients

NCT02998151
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 4, 2026, 8:38 PM EDT
Not yet recruiting Not applicable Interventional

A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease

NCT07553377
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Associated Liver Disease, Medications for Alcohol Use Disorder, Behavioral Medicine, Medication Adherence
Interventions
AcamproSync
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

NCT00591565
View directory record Official record
Conditions
Anxiety
Interventions
Acamprosate
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 4, 2026, 8:38 PM EDT
Terminated Phase 4 Interventional Results available

Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees

NCT00249379
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 3 Interventional

COMBINE (Acamprosate/Naltrexone)

NCT00006206
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
12
States / cities
New Haven, Connecticut • Miami, Florida • Belmont, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2010 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate vs. Placebo in Bipolar Alcoholics

NCT00466661
View directory record Official record
Conditions
Alcohol Dependence, Bipolar Disorder
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 4, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Results available

Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic

NCT00381043
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 4, 2026, 8:38 PM EDT